The study of the dose-dependent antiexudative effect of a new anti-inflammatory nasal spray
Keywords:acute rhinosinusitis, Enisamium iodide nasal spray, Ibuprofen, anti-inflammatory activity, dose-dependent effect
It is possible to assume that intranasal forms of drugs with the anti-inflammatory effect (AIE) can be effective for the pathogenic therapy of acute rhinosinusitis (ARS) to relieve nasal congestion.
Aim. To determine AIE of Enisamium iodide (EI), assess the dose dependence of the effect, and substantiate the choice of the concentration for the active substance of EI in the form of a nasal spray for external use.
Materials and methods. Enisamium iodide nasal spray – “Amizon” manufactured by JSC Farmak (Ukraine) was used in different concentrations extracutaneously. As a reference drug Ibuprofen – “Nurofen”, film-coated tablets, 200 mg, was used intragastrically in the dose of 48 mg/kg. The primary screening for the study of EI antiexudative action in three concentrations was conducted on the carrageenan-induced acute inflammatory model in rats. The anti-inflammatory activity (AIA) of EI in the concentrations of 5, 10 and 20 mg/ml was assessed in three hours compared to Ibuprofen.
Results. EI in all studied concentrations had a statistically significant anti-inflammatory activity of various degrees with a non-linear character in the route of administration studied and the concentration range selected. Therefore, the choice of the most optimal concentration of EI (nasal spray) was on the basis of the comparative analysis of AIA of the drug test samples studied. The most pronounced AIA (35.3 %) was in the EI concentration of 10 mg/ml. This concentration is recommended for further preclinical studies.
Conclusions. The study of AIA of Enisanium iodide (nasal spray) in the range of concentrations of 5, 10 and 20 mg/ml has shown the “activity-concentration” non-linear dependence. The most pronounced AIA is in the EI concentration of 10 mg/ml. Enisamium iodide (nasal spray) is a promising drug for further preclinical studies.
Fokkens, W. J., Lund, V. J., Mullol, J. et al. (2012). EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. Asummary for otorhinolaryngologists. Rhinology, 50 (1), 1–12.
Chow, A. W., Benninger, M. S., Brook, I. et al. (2012). Infectious Diseases Society of IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin. Infect. Dis.,54 (8), e72–e112.
Nakaz MOZ Ukrainy №85 vid 11.02.2016. Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Hostryi rynosynusyt. Kyiv: MOZ Ukrainy.
4. Nakaz MOZ Ukrainy №921 vid 16.11.2012. Instruktsiia dlia medychnoho zastosuvannia preparatu «Amizon®». Available at: http://mozdocs.kiev.ua/likiview.php?id= 31489
Kovalenko, V. N. (2016). Kompendium 2016 – lekarstvennye preparaty. K.: Morion, 2416.
Sigidin, Ya. A., Shvartc, G. Ya., Arzamastcev, A. P., Liberman, S. S. (1988). Lekarstvennaia terapiia vospalitelnogo protcessa: eksperimentalnaia i klinicheskaia farmakologiia protivovospalitelnykh preparatov. Moscow: Meditcina, 240.
Nakaz MOZ Ukrainy № 461 vid 22.06.2012. Instruktsiia dlia medychnoho zastosuvannia preparatu «Nurofen». Available at: http://mozdocs.kiev.ua/likiview.php?id=31317
Stefanov, A. V. (2002). Doklinicheskie issledovaniia lekarstvennykh sredstv. Kiev: Avitcenna, 528.
Kozhemiakin, Yu. M., Khromov, O. S., Filonenko, M. A., Saifetdinova, H. A. (2002). Naukovo–praktychni rekomendatsii z utrymannia laboratornykh tvaryn ta roboty z nymy. Kyiv: Derzhavnyi farmakolohichnyi tsentr MOZ Ukrainy, 155.
Guide for the care and use of laboratory animals, 8th edition. (2011).Washington: The National Academies Press, 246.
Sharp, P., Villano, J. S. (2012). The laboratory rat, 2nd edition. CRC Press, 399.
European convention for the protection of vertebrate animals used for experimental and other scientific purpose : Council of Europe. (1986).Strasbourg, 52.
Good Laboratory Practice (2005). OECD principles and guidance for compliance monitoring. OECD.
Zakon Ukrainy №3447–IV vid 21.02.2006 r. zi zminamy. Pro zakhyst tvaryn vid zhorstokoho povodzhennia. Available at: http://www.president.gov.ua/documents/3447–iv–3976
Lapach, S. N., Chubenko, A. V., Babych, P. N. (2000). Statisticheskie metody v mediko–biologicheskikh issledovaniiakh s ispolzovaniem Excel.Kiev: Morion, 320.
Prozorovskii, V. B. (2007). Psikhofarmakologiia i biologicheskaia narkologiia, 7 (3–4), 2090–2120.
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).